| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Factor Xa (fXa), a serine protease in the coagulation cascade. The compound binds the active site of fXa, inhibiting its ability to cleave prothrombin to thrombin. This reduces thrombin-mediated fibrin formation and platelet activation. Selectivity over other serine proteases and hERG channels (Ki = 1.8 μM) contributes to its safety profile.
|
|---|---|
| ln Vitro |
In a patch-clamp hERG test, betrixaban (PRT054021) has an IC50 of 8.9 μM [1]. Betrixaban's IC50 and Ki against plasma kallikrein are 6.3 μM and 3.5 μM, respectively [1]. Compared to all other medications (hERG Ki ⩽0.5 μM), betrixaban (hERG Ki 1.8 μM) exhibits noticeably decreased hERG activity [1]. Betrixaban (5-25 ng/mL) prevents the synthesis of thrombin [3].
Betrixaban HCl inhibits factor Xa with an IC50 of 1.5 nM and a Ki of 0.117 nM. It is highly selective and orally efficacious, with antithrombotic effects in preclinical models. It shows low potential for hERG-related cardiac effects (IC50 = 8.9 μM), indicating a wide safety margin. |
| ln Vivo |
In dogs, betrixaban (0.5 mg/kg intravenously; 2.5 mg/kg orally) has a 51.6% bioavailability [1]. In monkeys, betrixaban has a bioavailability of 58.7% (0.75 mg/kg via intravenous injection and 7.5 mg/kg via oral administration) [1]. r-Antidote reversed the rise in whole blood INR caused by betrixaban. Following a 30-minute intravenous infusion, betrixaban's total plasma concentration was 0.2 ± 0.01 μM, and 40% ± 7.2% of the inhibitor was unbound. Following the delivery of r-Antidote, the proportion of unbound inhibitor dropped to 0.3%±0.1% and the total plasma concentration increased to 2.0±0.4 μM[2]. The suppression of thrombus mass by betrixaban (3 mg/kg) in the rabbit intraperitoneal vein model of clot accumulation on cotton threads was nearly equal to that of enoxaparin 1.6 mg/kg (76% vs. 96% inhibition) [3]. Trixaban (19.1 mg/kg) was at least as efficient as enoxaparin 7.6 mg/kg and clopidogrel 3 mg/kg/d in maintaining patency (patency rates, respectively, 90% vs. 70% vs. 80%) in a carotid artery in a mouse model of ferric chloride damage [3].
In vivo, betrixaban HCl demonstrates antithrombotic efficacy in animal models of venous and arterial thrombosis. It is orally bioavailable and has been evaluated clinically for VTE prophylaxis in acutely ill medical patients. Its pharmacokinetics and safety profile are characterized in clinical trials. |
| Enzyme Assay |
In vitro factor Xa inhibition assays use purified human fXa incubated with a chromogenic substrate (e.g., S-2222) in the presence of the compound. The release of p-nitroaniline is measured spectrophotometrically at 405 nm, and IC50 values are derived from dose-response curves. Ki values are calculated using Cheng-Prusoff analysis.
|
| Cell Assay |
In vitro cell-based assays for anticoagulants typically measure thrombin generation in plasma or whole blood using calibrated automated thrombography (CAT). Compound is added to plasma, and thrombin generation parameters (lag time, peak, endogenous thrombin potential) are quantified. Platelet activation and coagulation factor activation can also be assessed.
|
| Animal Protocol |
In vivo animal experiments use rodent or rabbit models of venous thrombosis (e.g., vena cava ligation or FeCl₃-induced thrombosis). Betrixaban HCl is administered orally at doses guided by pharmacokinetic studies. Efficacy is assessed by thrombus weight, blood flow restoration, and biomarkers of coagulation activation (e.g., D-dimer, thrombin-antithrombin complexes).
|
| References |
|
| Molecular Formula |
C23H23CL2N5O3
|
|---|---|
| Molecular Weight |
488.366422891617
|
| Exact Mass |
487.117
|
| CAS # |
2099719-47-6
|
| Related CAS # |
Betrixaban;330942-05-7;Betrixaban maleate;936539-80-9
|
| PubChem CID |
16717958
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
107
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
33
|
| Complexity |
668
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl.Cl
|
| InChi Key |
ZLQLCRUMXURJFC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H22ClN5O3.ClH/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20;/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31);1H
|
| Chemical Name |
N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide;hydrochloride
|
| Synonyms |
Betrixaban hydrochloride; PRT-054021 hydrochloride; PRT054021 hydrochloride; 2099719-47-6; Betrixabanhydrochloride; Betrixaban (hydrochloride); PRT054021 hydrochloride;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0476 mL | 10.2381 mL | 20.4763 mL | |
| 5 mM | 0.4095 mL | 2.0476 mL | 4.0953 mL | |
| 10 mM | 0.2048 mL | 1.0238 mL | 2.0476 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.